vs
PROGRESS SOFTWARE CORP（PRGS）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
PROGRESS SOFTWARE CORP的季度营收约是VERACYTE, INC.的1.8倍（$252.7M vs $140.6M），VERACYTE, INC.净利率更高（29.3% vs 10.2%，领先19.1%），VERACYTE, INC.同比增速更快（18.5% vs 17.5%），PROGRESS SOFTWARE CORP自由现金流更多（$59.9M vs $48.8M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 17.0%）
Progress Software是全球领先的企业级软件服务商，主营应用开发平台、数据连接工具、数字体验解决方案等产品，服务覆盖金融、医疗、制造、零售等多行业的全球企业客户，助力客户搭建高性能可扩展的业务应用，提升运营效率。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
PRGS vs VCYT — 直观对比
营收规模更大
PRGS
是对方的1.8倍
$140.6M
营收增速更快
VCYT
高出1.0%
17.5%
净利率更高
VCYT
高出19.1%
10.2%
自由现金流更多
PRGS
多$11.1M
$48.8M
两年增速更快
VCYT
近两年复合增速
17.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $252.7M | $140.6M |
| 净利润 | $25.7M | $41.1M |
| 毛利率 | 81.6% | 72.5% |
| 营业利润率 | 15.2% | 26.4% |
| 净利率 | 10.2% | 29.3% |
| 营收同比 | 17.5% | 18.5% |
| 净利润同比 | 2144.6% | 704.8% |
| 每股收益（稀释后） | $0.59 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGSVCYT
| Q4 25 | $252.7M | $140.6M | ||
| Q3 25 | $249.8M | $131.9M | ||
| Q2 25 | $237.4M | $130.2M | ||
| Q1 25 | $238.0M | $114.5M | ||
| Q4 24 | $215.0M | $118.6M | ||
| Q3 24 | $178.7M | $115.9M | ||
| Q2 24 | $175.1M | $114.4M | ||
| Q1 24 | $184.7M | $96.8M |
净利润PRGSVCYT
| Q4 25 | $25.7M | $41.1M | ||
| Q3 25 | $19.4M | $19.1M | ||
| Q2 25 | $17.0M | $-980.0K | ||
| Q1 25 | $10.9M | $7.0M | ||
| Q4 24 | $1.1M | $5.1M | ||
| Q3 24 | $28.5M | $15.2M | ||
| Q2 24 | $16.2M | $5.7M | ||
| Q1 24 | $22.6M | $-1.9M |
毛利率PRGSVCYT
| Q4 25 | 81.6% | 72.5% | ||
| Q3 25 | 81.0% | 69.2% | ||
| Q2 25 | 80.1% | 69.0% | ||
| Q1 25 | 80.6% | 69.5% | ||
| Q4 24 | 83.0% | 66.4% | ||
| Q3 24 | 83.7% | 68.2% | ||
| Q2 24 | 81.7% | 68.1% | ||
| Q1 24 | 82.2% | 64.5% |
营业利润率PRGSVCYT
| Q4 25 | 15.2% | 26.4% | ||
| Q3 25 | 17.6% | 17.4% | ||
| Q2 25 | 16.3% | -4.0% | ||
| Q1 25 | 13.6% | 2.5% | ||
| Q4 24 | 10.0% | 3.5% | ||
| Q3 24 | 22.6% | 10.4% | ||
| Q2 24 | 15.5% | 4.0% | ||
| Q1 24 | 19.0% | -4.8% |
净利率PRGSVCYT
| Q4 25 | 10.2% | 29.3% | ||
| Q3 25 | 7.8% | 14.5% | ||
| Q2 25 | 7.2% | -0.8% | ||
| Q1 25 | 4.6% | 6.2% | ||
| Q4 24 | 0.5% | 4.3% | ||
| Q3 24 | 15.9% | 13.1% | ||
| Q2 24 | 9.2% | 5.0% | ||
| Q1 24 | 12.3% | -1.9% |
每股收益（稀释后）PRGSVCYT
| Q4 25 | $0.59 | $0.50 | ||
| Q3 25 | $0.44 | $0.24 | ||
| Q2 25 | $0.39 | $-0.01 | ||
| Q1 25 | $0.24 | $0.09 | ||
| Q4 24 | $0.01 | $0.07 | ||
| Q3 24 | $0.65 | $0.19 | ||
| Q2 24 | $0.37 | $0.07 | ||
| Q1 24 | $0.51 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $94.8M | $362.6M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $478.3M | $1.3B |
| 总资产 | $2.5B | $1.4B |
| 负债/权益比越低杠杆越低 | 2.93× | — |
8季度趋势，按日历期对齐
现金及短期投资PRGSVCYT
| Q4 25 | $94.8M | $362.6M | ||
| Q3 25 | $99.0M | $315.6M | ||
| Q2 25 | $102.0M | $219.5M | ||
| Q1 25 | $124.2M | $186.1M | ||
| Q4 24 | $118.1M | $239.1M | ||
| Q3 24 | $232.7M | $274.1M | ||
| Q2 24 | $190.4M | $235.9M | ||
| Q1 24 | $133.2M | $209.2M |
总债务PRGSVCYT
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PRGSVCYT
| Q4 25 | $478.3M | $1.3B | ||
| Q3 25 | $477.7M | $1.3B | ||
| Q2 25 | $452.7M | $1.2B | ||
| Q1 25 | $431.8M | $1.2B | ||
| Q4 24 | $438.8M | $1.2B | ||
| Q3 24 | $425.6M | $1.2B | ||
| Q2 24 | $401.7M | $1.1B | ||
| Q1 24 | $461.7M | $1.1B |
总资产PRGSVCYT
| Q4 25 | $2.5B | $1.4B | ||
| Q3 25 | $2.4B | $1.4B | ||
| Q2 25 | $2.4B | $1.3B | ||
| Q1 25 | $2.5B | $1.3B | ||
| Q4 24 | $2.5B | $1.3B | ||
| Q3 24 | $1.6B | $1.3B | ||
| Q2 24 | $1.6B | $1.2B | ||
| Q1 24 | $1.5B | $1.2B |
负债/权益比PRGSVCYT
| Q4 25 | 2.93× | — | ||
| Q3 25 | 2.97× | — | ||
| Q2 25 | 3.22× | — | ||
| Q1 25 | 3.50× | — | ||
| Q4 24 | 3.48× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $62.8M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $59.9M | $48.8M |
| 自由现金流率自由现金流/营收 | 23.7% | 34.7% |
| 资本支出强度资本支出/营收 | 1.1% | 2.7% |
| 现金转化率经营现金流/净利润 | 2.44× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $229.5M | $126.6M |
8季度趋势，按日历期对齐
经营现金流PRGSVCYT
| Q4 25 | $62.8M | $52.6M | ||
| Q3 25 | $73.4M | $44.8M | ||
| Q2 25 | $30.0M | $33.6M | ||
| Q1 25 | $68.9M | $5.4M | ||
| Q4 24 | $19.7M | $24.5M | ||
| Q3 24 | $57.7M | $30.0M | ||
| Q2 24 | $63.7M | $29.6M | ||
| Q1 24 | $70.5M | $-9.0M |
自由现金流PRGSVCYT
| Q4 25 | $59.9M | $48.8M | ||
| Q3 25 | $72.4M | $42.0M | ||
| Q2 25 | $29.5M | $32.3M | ||
| Q1 25 | $67.7M | $3.5M | ||
| Q4 24 | $16.8M | $20.4M | ||
| Q3 24 | $56.6M | $27.7M | ||
| Q2 24 | $62.7M | $26.8M | ||
| Q1 24 | $70.2M | $-11.1M |
自由现金流率PRGSVCYT
| Q4 25 | 23.7% | 34.7% | ||
| Q3 25 | 29.0% | 31.8% | ||
| Q2 25 | 12.4% | 24.8% | ||
| Q1 25 | 28.4% | 3.1% | ||
| Q4 24 | 7.8% | 17.2% | ||
| Q3 24 | 31.7% | 23.9% | ||
| Q2 24 | 35.8% | 23.4% | ||
| Q1 24 | 38.0% | -11.5% |
资本支出强度PRGSVCYT
| Q4 25 | 1.1% | 2.7% | ||
| Q3 25 | 0.4% | 2.1% | ||
| Q2 25 | 0.2% | 1.0% | ||
| Q1 25 | 0.5% | 1.6% | ||
| Q4 24 | 1.3% | 3.5% | ||
| Q3 24 | 0.6% | 1.9% | ||
| Q2 24 | 0.5% | 2.4% | ||
| Q1 24 | 0.2% | 2.2% |
现金转化率PRGSVCYT
| Q4 25 | 2.44× | 1.28× | ||
| Q3 25 | 3.78× | 2.34× | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | 6.30× | 0.76× | ||
| Q4 24 | 17.13× | 4.80× | ||
| Q3 24 | 2.03× | 1.98× | ||
| Q2 24 | 3.93× | 5.16× | ||
| Q1 24 | 3.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
